congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
DS-1103, T-DXd
ESMO 2023 | October 20-24, 2023
A phase 1, 2-part, multicenter, first-in-human, dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Oral
T-DXd
ESMO 2023 | October 20-24, 2023
A pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer with brain metastases from DESTINY-Breast01, -02, and -03
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
Baseline circulating tumor DNA biomarker analysis of patients with human epidermal growth factor receptor 2 overexpressing metastatic non–small cell lung cancer treated with trastuzumab deruxtecan
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
Characteristics, treatment patterns, and outcomes of patients with advanced/metastatic gastric cancer or gastro-esophageal junction adenocarcinoma previously treated with anti-HER2 therapy in an English national registry
Mini-Oral
Dato-DXd
ESMO 2023 | October 20-24, 2023
Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase 1b/2 study
Oral
Dato-DXd
ESMO 2023 | October 20-24, 2023
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer: Primary results from the randomised phase 3 TROPION-Breast01 trial
Oral
Dato-DXd
ESMO 2023 | October 20-24, 2023
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Oral
T-DXd
ESMO 2023 | October 20-24, 2023
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors harboring specific activating HER2 mutations: Primary results from the international phase 2 DESTINY-PanTumor01 study
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
HER2 testing patterns: Characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France